Dr. Richard J Johnson Jr., MD
Professor of Pediatrics and Associate Dean for Research and Development, University of Colorado School of Medicine
Dr. Henk E. D. J. ter Keurs, MD, PhD
Cardiologist, LiBIN Cardiovascular Institute of Alberta
Dr. Petter Bjornstad, MD
Clinical Researcher and Assistant Professor of Pediatrics and Medicine, University of Colorado School of Medicine
Dr. Fred Maese, MD
Cardiologist and Clinical Researcher
Dr. Anjay Rastogi, MD PhD
Professor and Clinical Chief of Nephrology, David Geffen School of Medicine, UCLA
Dr. Charles Edelstein, MD PhD
Professor of Medicine and Nephrologist, University of Colorado, Denver
Dr. Ronald Perrone
Professor of Medicine at Tufts University School of Medicine
Dr. Ronald Perrone, MD is Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts. Dr. Perrone is board certified in Nephrology. He did his Internal Medicine residency at Grady Memorial Hospital in Atlanta and Nephrology fellowship at Boston University Medical Center. Ron’s research involves clinical investigations focused on kidney disease with a special emphasis on polycystic kidney disease (“PKD”). He is heavily involved in clinical research in ADPKD clinical trials and works with regulatory agencies such as the US Food and Drug Administration (“FDA”) to contribute to the development of database assessment tools to validate total kidney volume as a biomarker for PKD progression. Dr. Perrone’s focus on translational clinical trial interventions in ADPKD includes trials for Sanofi, Reata, Palladio Biosciences, HALT-PKD, the TAME PKD Metformin trial, TEMPO and REPRISE trials for Tolvaptan. Ron also initiated a PKD Database Consortium in 2007 which led to the creation of the PKD Outcomes Consortium in 2009. The PKD Outcomes Consortium, comprising contributors from academia, the pharmaceutical industry, National Institute of Health (“NIH”), FDA, the Clinical Data Interchange Standards Consortium (“CDISC”), and the Critical Path Institute (C-Path), is creating the groundwork for validation of for biomarkers and clinical trial and regulatory endpoints in ADPKD. This work is ongoing and involves frequent interactions with the FDA and the European Medicines Agency.